About
NeuroHagana (NH) develops an injectable emergency treatment for neurotrauma, irrespective of its type or severity. The novel treatment acts immediately to protect against the main factor in Neurotrauma pathology: Glutamate Excitotoxicity.
NH’s technology has been pre-clinically validated in animal models of Spinal Cord Injury, Traumatic Brain Injury, and Athletes Concussion, with no side effects. The new treatment reduces the toxic impact of excessive Glutamate levels in the Central Nervous System, preventing irreversible neuronal damage and physical disabilities. First applications will be Spinal Cord Injury, first in Europe and USA. Other applications will be Traumatic Brain Injury and Stroke.
Essential for paramedics, hospital trauma units, first aid teams and military forces, the new innovative drug aims to become a vital component of any core emergency kit, preventing permanent disabilities of the injured people and giving them the opportunity to regain their freedom.
Q&A
- What is NeuroHagana's primary focus?
- NeuroHagana develops an injectable emergency treatment for neurotrauma, aiming to prevent permanent disabilities by protecting against Glutamate Excitotoxicity.
- When was NeuroHagana founded?
- NeuroHagana was founded in March 2023.
- What is the current employee count for NeuroHagana?
- NeuroHagana has 5 employees, falling into the 1-10 employee bucket.
- What is the current funding stage of NeuroHagana?
- NeuroHagana is currently in the Pre-Funding stage.
- In which sector does NeuroHagana primarily operate?
- NeuroHagana's primary sector is Health Tech & Life Sciences, specifically within Pharma & Medical Biotechnology and Drugs Discovery & Development.
- What are the initial applications for NeuroHagana's treatment?
- The first applications for NeuroHagana's treatment will be for Spinal Cord Injury, initially in Europe and the USA, with future applications for Traumatic Brain Injury and Stroke.
- Has NeuroHagana's technology been pre-clinically validated?
- Yes, NeuroHagana's technology has been pre-clinically validated in animal models of Spinal Cord Injury, Traumatic Brain Injury, and Athletes Concussion, with no reported side effects.
- Does NeuroHagana hold any patents?
- Yes, NeuroHagana holds 1 patent.
Team · 2
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | neurohagana.com |
|---|---|
| linkedin.com/in/angela-ruban-a8b71423/ |
Identifiers & details
| Founded | 2023-3 |
|---|---|
| Employees (exact) | 5 |
Radar intelligence
Web history (Wayback)
| Domain | neurohagana.com |
|---|
Certificate / subdomain footprint
| Subdomains | 3 |
|---|